Primary Prevention: The 'Striking' Benefit of Lowering Lipids.
Originally Published 2 years ago — by Medscape

A new analysis of the CLEAR Outcomes trial of bempedoic acid has shown a 30% relative risk reduction in the composite of cardiovascular death, myocardial infarction (MI), stroke, or coronary revascularization in high-risk primary prevention patients, two thirds of whom also had type 2 diabetes. The study's lead investigator, Dr. Steve Nissen, called the results "frankly striking" and emphasized the need for more attention to be paid to this group of patients, who are often not well treated. Nissen recommends that high-risk primary prevention patients, particularly those with type 2 diabetes, should be treated with a lipid-lowering drug, such as a statin or bempedoic acid.
